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ABSTRACT: An antikinetoplastid pharmacomodulation study was conducted at position 6 of
the 8-nitroquinolin-2(1H)-one pharmacophore. Fifteen new derivatives were synthesized and
evaluated in vitro against L. infantum, T. brucei brucei, and T. cruzi, in parallel with a cytotoxicity
assay on the human HepG2 cell line. A potent and selective 6-bromo-substituted
antitrypanosomal derivative 12 was revealed, presenting EC50 values of 12 and 500 nM on
T. b. brucei trypomastigotes and T. cruzi amastigotes respectively, in comparison with four
reference drugs (30 nM ≤ EC50 ≤ 13 μM). Moreover, compound 12 was not genotoxic in the
comet assay and showed high in vitro microsomal stability (half life >40 min) as well as
favorable pharmacokinetic behavior in the mouse after oral administration. Finally, molecule 12
(E° = −0.37 V/NHE) was shown to be bioactivated by type 1 nitroreductases, in both
Leishmania and Trypanosoma, and appears to be a good candidate to search for novel
antitrypanosomal lead compounds.
KEYWORDS: Trypanosoma brucei brucei, Trypanosoma cruzi, 8-nitroquinolin-2(1H)-ones, redox potentials, NTR1
Human African trypanosomiasis (HAT),1 Chagas diseases(CD),2 and visceral leishmaniasis (VL)3 are infectious
diseases caused by unicellular flagellated kinetoplastid parasites
belonging to the Trypanosoma and Leishmania genera. From an
epidemiological point of view, the World Health Organization
(WHO) estimates that millions of people are at risk of
contracting HAT, CD, and VL. These three diseases are also
estimated to be responsible for about 30 000 annual deaths,
with the caveat that these numbers may be underestimated due
to the difficulty in accessing some rural areas and the unspecific
symptoms during the early stage of these infections.4 Although
these diseases are lethal if untreated, there are very few efficient
and safe drugs available, each of them presenting various
drawbacks for the patient (toxicity, emergence of resistances,
mode of administration, treatment cost). Thus because of the
lack of consideration and investments from the pharmaceutical
industry, the WHO classified HAT, CD, and VL among
“neglected tropical diseases” (NTDs).5
In this context, nitroaromatic derivatives play a key role in
the fight against kinetoplastids (Figure 1). Beyond Nifurtimox
and Benznidazole (antitrypanosomal drugs), nitroaromatics are
fully part of the research efforts of the Drugs for Neglected
Diseases initiative (DNDi). Thus among the few novel
chemical entities in clinical trials against these infections,6
the development of fexinidazole (an orally available 5-
nitroimidazole derivative that received an agreement from
the European Medicines Agency (EMA) in the treatment of
HAT in 2018 and that is in phase 2 against CD),7−9 delamanid
(a derivative that is marketed against tuberculosis and that was
studied against VL),10 and DNDi-0690 (a 2-nitroimidazoox-
azine derivating from delamanid and that has recently entered
phase-I clinical trials against VL) illustrate well the strong
potential of nitroaromatic molecules in the search for novel
antitrypanosomatids.11
The antiparasitic mechanism of action of these molecules
involves parasitic nitroreductases (NTRs). NTRs contain a
flavin as a cofactor and catalyze the one- or two-electron
reduction of nitrodrugs into cytotoxic electrophilic metabolites
such as nitroso and hydroxylamine derivatives, which are able
to form covalent adducts with DNA or proteins.12 Two NTRs
were found in Leishmania: a mitochondrial NTR1 catalyzing a
two-electron reduction13 and a cytosolic NTR2 catalyzing a
one-electron reduction.14 In Trypanosoma, only a mitochon-
drial type 1 NTR is expressed.15,16 It is important to note that
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these enzymes are absent from mammalian cells, an important
feature for developing selective antikinetoplastid molecules.
Moreover, depending on the chemical structure of nitrated
derivatives, the selectivity for NTRs could be modulated. For
instance, fexinidazole is selectively bioactivated by NTR1 in
both Leishmania and Trypanosoma; meanwhile, delamanid is
only bioactivated by NTR2 in Leishmania.14
In this context, by studying the antiparasitic potential of the
8-nitroquinoline scaffold,17 our research team reported a new
antileishmanial pharmacophore: 8-nitroquinolin-2(1H)-one.18
After pharmacomodulation studies at position 4,19,20 an
electrochemistry-guided work highlighted the importance of
an intramolecular hydrogen bond between the nitro group and
the lactam function.21 This work also led to the identification
of a new 3-bromosubstituted antikinetoplastid hit compound
derivative (Hit 1, Figure 2), which is bioactivated by type 1
NTRs, in both L. donovani and T. brucei brucei (T. b. brucei).21
Recently, by introducing a p-carboxyphenyl functionality at
position 3 of the pharmacophore, we reported a new selective
antitrypanosomal hit compound (Hit 2, Figure 2).22
We herein present a medicinal chemistry work that greatly
improved the antitrypanosomal activity of the current series via
the synthesis of novel derivatives bearing electron-withdrawing
groups at position 6 of the quinolinone scaffold.
To increase the oxidant character of the series and facilitate
its bioactivation by nitroreductases, 15 derivatives (1−15)
were prepared, bearing various electron-withdrawing groups
(EWGs) at position 6. As presented in Scheme 1, eight
compounds bearing a trifluoromethyl group at position 6 of
the quinolinone scaffold were synthesized according to a
previously reported protocol.23 In brief, 3-ethoxyacryloyl
chloride was synthesized in two steps by the saponification
Figure 1. Structures of nitroaromatic drugs displaying antikinetoplastid activity.
Figure 2. Antitrypanosomatid profile of previously reported 8-nitroquinolin-2(1H)-one hit compounds.
Scheme 1. Synthesis of Compounds 1−8 from p-Trifluoromethylaniline
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of commercial 3,3′-diethoxyethylpropionate followed by a
reaction with thionyl chloride. This acyl chloride was then
reacted with p-trifluoromethylaniline to afford, after a
cyclization step in H2SO4 (98%), compound 1 in 42% yield
(a). Molecule 1 was then either nitrated at position 8, using
classical conditions, to afford compound 2 in 89% yield (b) or
selectively halogenated at position 3 to generate derivative 3 or
4 in 48 and 54% yield, respectively (c and d). The O-
methylation of compound 2 was performed with a protocol
using a mixture of methyl iodide and sodium hydride to
prepare derivative 5 in 69% yield (e). Nitrated molecule 2
could also undergo chlorination at position 3, affording
compound 6 in 88% yield (f), or react with NaBrO3 in
refluxing HBr, according to a previously reported protocol,24 to
afford halogenated derivative 7 in 94% yield (g). The nitro
group of compound 7 was finally reduced to afford the amino-
derivative 8, considered as a negative control, using SnCl2, in
68% yield (h).
The synthesis pathway used for preparing derivatives bearing
a halogen atom at position 6 of the quinolinone ring is
presented in Scheme 2. It starts from 8-nitroquinolin-2(1H)-
one,21 which was reacted with bromine in refluxing acetic acid,
saturated with sodium acetate, leading to a mixture of both 6-
bromo and 3,6-dibromo derivatives 9 and 10 in 9 and 33%
yield, respectively (a). Dichloro analogue 11 was also prepared
from 8-nitroquinolin-2(1H)-one by reacting with 5 equiv of
sodium chlorate in refluxing hydrochloric acid for 24 h (b). By
using the same reaction, decreasing the amount of sodium
chlorate to 3 equiv, and limiting the reaction time to 45 min, 3-
chloro-8-nitroquinolin-2(1H)-one was formed (c).21 This
compound could be brominated at position 6 by reacting
with an excess of NaBrO3 in refluxing HBr, leading to 12 in
good yield (d). Taking into account that we previously
reported the benefit of introducing a p-carboxyphenyl moiety
at position 3 of the scaffold toward antitrypanosomal activity,22
we finally engaged dibromo-derivative 10 into a Suzuki−
Miyaura reaction with p-(methoxycarbonyl)phenylboronic acid
and then saponified the resulting ester coupling product to
afford carboxylic acid 13 (e). Finally, from brominated
compound 12, derivatives 14 and 15 were obtained through
a Sonogashira coupling reaction (f).
Scheme 2. Synthesis of Compounds 9−15
Figure 3. Redox potentials of synthesized nitroaromatic compounds determined by cyclic voltammetry.
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Table 1. Antikinetoplastid Activities and Cytotoxicity of Compounds 1−15
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Electrochemistry. Because the compounds were expected
to be nitroreductase substrates, we studied the influence of the
introduction of EWGs at position 6 of the pharmacophore
toward redox potentials. Thus redox potentials (couple R-
NO2/RNO2
•−) of the synthesized compounds were measured
by cyclic voltammetry in DMSO (one-electron reversible
reduction). Redox potentials ranged between −0.36 and −0.75
V/NHE (Figure 3). In comparison with the original
pharmacophore, the introduction of a bromine atom at
position 6 (compound 9) led to a significant increase in the
E° value from −0.54 to −0.40 V. The same effect was observed
when a bromine atom was introduced at position 6 of hit 2
(compound 13), with an increase in the E° value of +0.16 V. It
is important to note that introducing a bromine atom has a
higher influence on the redox potential at position 6
(compound 9) compared with position 3 (hit 1): +0.14
versus +0.09 V. The influence of the CF3 group toward the
redox potential of the scaffold was the same as that of the
bromine atom: +0.15 V (comparison between the pharmaco-
phore and compound 2). Then, when two bromine atoms were
combined at positions 3 and 6 (compound 10), a slight
increase of +0.03 V was observed (no additive effect) in
comparison with 6-bromo-derivative 9. Surprisingly, by
comparing compounds 7 and 10−12, there was almost no
effect of the variation of the EWG at position 3 or 6 toward the
redox potential values, with all compounds ranging from −0.36
to −0.37 V. Finally, by comparing compound 2 with its O-
methylated derivative 5, it appeared that the redox potential
value was drastically lower (−0.36 V shift). This shift is not
only due to the donating mesomeric effect of the methoxy
group but also due to the disappearance of the intramolecular
hydrogen bond between the nitro group and the lactam
function.21
Compound Evaluation. The cytotoxicity of all com-
pounds was first assessed on the human HepG2 cell line using
doxorubicin as a positive control (Table 1). Compared with
this reference drug (CC50 = 0.2 μM), the series showed little
(CC50 = 17 μM) to no (CC50 > 100 μM) cytotoxicity. Non-
nitrated molecules 1, 3, and 4, O-methylated derivative 5, and
8-amino-derivative 8, considered as negative controls, dis-
played high CC50 values, >100 μM. The results show that the
introduction of a bromine atom or a CF3 group at position 6 of
the nitrated scaffold leads to derivatives (2 and 9) that are four
to five times more cytotoxic (CC50 = 28−41 μM) than the 8-
nitroquinolinone pharmacophore (CC50 = 164 μM). When
introducing an additional halogen atom at position 3 of the
scaffold (6, 7, 10−12), the cytotoxicity remains close to the
ones of 6-monosubstituted derivatives (CC50 = 17−41 μM).
Nevertheless, introducing a p-carboxyphenyl functionality at
position 3 of the scaffold (compound 13) results in a three-fold
decrease in the cytotoxicity (CC50 = 60 μM) in comparison
with the 3,6-dibromo derivative 10 (CC50 = 17 μM).
All synthesized molecules were screened in vitro for their
activity against Leishmania infantum axenic amastigotes, and
their EC50 values were compared with the ones of three
reference drugs (amphotericin B, miltefosine, and fexinidazole)
and antikinetoplastid hit 1 (Table 1). Among the tested
compounds, only compound 7 (E° = −0.36 V) showed a weak
antileishmanial activity, displaying an EC50 value of 3.9 μM in
addition to a selectivity index superior to 10. Derivatives of 7
without a nitro group at position 8 of the scaffold (1, 3, 4, and
8) were inactive toward L. infantum as well as the O-
methylated analogue 5 (E° = −0.75 V), confirming both the
key role of the nitro group toward antiparasitic activity and the
importance of the interaction between the nitro group and the
lactam function to confer suitable redox potentials for
displaying antileishmanial properties in this chemical series.21
Note that, contrary to hit 2, which was not active against L.
infantum (EC50 > 100 μM), the 6-bromo derivative 13 was
active (EC50 = 8 μM).
All molecules were also screened in vitro for their
antitrypanosomal activity against T. b. brucei trypomastigotes,
and their EC50 values were compared with the ones of three
reference drugs, suramin, eflornithine, and fexinidazole, and
with antitrypanosomal hit 2. Among the 15 tested molecules,
7, 9, 10, 11, 12, and 13 displayed both submicromolar activity
(12 ≤ EC50 ≤ 200 nM) and good selectivity indices (SI > 200)
in comparison with suramin (EC50 = 30 nM), eflornithine
(EC50 = 13 μM), fexinidazole (EC50 = 400 nM), and hit 2
(EC50 = 1.5 μM). Molecule 12 was the most active and
selective in the series: EC50 = 12 nM and SI = 1508.
Compounds without a nitro group at position 8 of the scaffold
Table 1. continued
aEC50 or CC50 value was not reached at the highest tested concentration.
bDoxorubicin was used as a cytotoxic reference drug. cAmphotericin B,
miltefosine, and fexinidazole were used as antileishmanial reference drugs. dFexinidazole, suramin, and eflornithine were used as anti-Trypanosoma
brucei reference drugs.
ACS Medicinal Chemistry Letters pubs.acs.org/acsmedchemlett Letter
https://dx.doi.org/10.1021/acsmedchemlett.9b00566
ACS Med. Chem. Lett. XXXX, XXX, XXX−XXX
E
appeared to be inactive (compounds 1, 3, and 4), and amino-
derivative 8 was quite less active (EC50 = 9 μM). It is
important to note that the introduction of a bromine atom at
position 6 of the scaffold seems crucial to afford highly active
antitrypanosomal molecules, with compound 9 being 334
times more active than the 8-nitroquinolin-2(1H)-one
pharmacophore and 27 times more active than its 3-bromo-
position isomer (hit 1). This key effect of the bromine atom at
position 6 of the scaffold also appears when comparing the
activities of 3-chloro-6-bromo hit-compound 12 with its 3-
chloro-analogue A: 12 is 100 times more active than A. When
comparing molecules 2 and 9, it appeared that the CF3 group
does not provide the same level of improvement in activity.
Introducing an additional halogen atom at position 3 of hit
molecule 9, leading to dibromo-derivative 10 and dihalo-
derivative 12, afforded the most active compounds in the series
(EC50 = 12−50 nM). A comparison between compound 12
and 3,6-dichlorosubstituted derivative 11 showed that the
replacement of the bromine atom by a chlorine atom at
position 6 was not in favor of antitrypanosomal activity. During
pharmacomodulation studies at position 3 of the scaffold, hit 2
was identified as a promising antitrypanosomal hit with an
EC50 of 1.5 μM.
22 When a bromine atom is introduced at
position 6 of hit 2, leading to compound 13, the
antitrypanosomal activity is improved, reaching an EC50
value of 200 nM.
Thus the molecule presenting the best antitrypanosomal
profile in the series, regarding both the activity and the
selectivity, was compound 12. To better evaluate its
antitrypanosomal potential, an in vitro evaluation against
intracellular T. cruzi amastigotes was carried out using
benznidazole and fexinidazole as positive controls (Table 1).
Quite interestingly, despite being about 10 times more
cytotoxic than reference drugs, molecule 12 displayed a high
activity (EC50 = 0.5 μM) against T. cruzi, identical to the one
of benznidazole (EC50 = 0.5 μM) and better than the one of
fexinidazole (EC50 = 3 μM).
To investigate more deeply the potential of compounds 7,
12, and 13 as the most active antikinetoplastid compounds of
the studied series, an in vitro pharmacokinetic evaluation was
performed, including a microsomal stability assay (female
mouse microsomes), a human albumin binding assay, and a
PAMPA assay using a blood−brain barrier (BBB) model
(Table 2). All compounds presented good microsomal stability
(T1/2 > 40 min) and strong binding to human albumin
(≥99%). However, the development of antitrypanosomal
agents requires that molecules cross the BBB, as the second
stage of HAT is meningoencephalitic. A PAMPA assay on a
BBB model was then performed.25,26 Compounds 7 and 12
diffused through the lipid bilayer with Pe values significantly
higher than the positive control (Pe = 450.3 and 405.1 nm/s,
respectively), whereas compound 13 displayed a low Pe value
(Pe = 12.7 nm/s), indicating a limited crossing of the BBB,
hindering the further development of 13. This last result is not
surprising because electrostatic repulsions between the
negatively charged carboxylic acid group of this molecule
and the negatively charged membrane constituents are
probably responsible for its low permeability across the BBB
in the PAMPA model. Moreover, 13 has a molecular weight
approaching 400 g/mol, which could also contribute to
limiting its diffusion across the BBB.27 Unfortunately, the
methylic ester precursor or 13 could not be evaluated in vitro
because of a lack of aqueous solubility. The ability of hit-
compound 12 to cross the BBB in the PAMPA assay is in
accordance with its central nervous system multiparameter
optimization (CNS MPO) score28 that has a calculated value
of 4.35. Finally, the aqueous solubility of hit-compound 12 was
measured with a thermodynamic solubility assay at physio-
logical pH and was determined at 21.7 μM (Table 2).
To check the antikinetoplastid mechanism of the bio-
activation of compounds 7, 12 and 13, their activities were
evaluated in vitro toward Leishmania donovani promastigote
strains overexpressing leishmanial nitroreductases (NTR1 or
NTR2). EC50 values were determined and compared with the
ones obtained on a wild-type strain to evaluate the
Table 2. In Vitro Pharmacokinetic, Physicochemical, and Toxicological Properties of Compounds 7, 12, and 13
aCalculated with MarvinSketch (ChemAxon).
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bioactivation of these nitroaromatic compounds (Table 3). As
reported for hit 1,21 compounds 7 and 12 are selectively
bioactivated by leishmanial NTR1, with EC50 values being 3.5
and 16 times lower on the strain overexpressing the NTR than
on the wild type. Contrary to 7 and 12, compound 13 did not
demonstrate significant bioactivation by NTR1 or by NTR2 in
Leishmania. The same experiments were carried out with
compounds 7, 12, and 13 on T. b. brucei strains overexpressing
the type 1 trypanosomal NTR, comparing the EC50 values with
the ones determined on the wild-type strain (Table 3). All
tested compounds were bioactivated by the type 1 nitro-
reductase of T. b. brucei, being, respectively, 7, 15, and 40 times
more active against the strain overexpressing the NTR than
against the wild type. It is interesting to note that hit 2 (E° =
−0.56 V) did not seem to be bioactivated by T. b. brucei NTR,
whereas its 6-brominated derivative 13 (E° = −0.40 V) was.
Finally, hit-compound 12 also appeared to be six times more
active than nifurtimox against T. b. brucei, underlining the
potential of this molecule as an antitrypanosomal candidate.
Even though many safe nitroaromatic molecules are today
on the market (for example, antiprotozoal 5-nitroimidazoles
such as metronidazole, several antihypertensive dihydropyr-
idines like nicardipine, some benzodiazepines like loprazolam,
anti-Parkinson’s catechol O-methyltransferase (COMT) in-
hibitors like entacapone, antiandrogens like flutamide, anti-
inflammatory nimesulide, immunomodulating azathioprine,
anticoagulant acenocoumarol, anthelminthic niclosamide,
etc.) or in clinical trials (for instance, delamanid), drugs
including a nitroaromatic moiety suffer from a bad reputation
as possible mutagenic or genotoxic molecules, which narrows
their pharmaceutical development.29 The Ames test is the most
commonly used assay to evaluate the mutagenic potential of
compounds, using Salmonella typhimurium strains. However,
these bacteria possess NTR, making the Ames test generally
unsuitable for the evaluation of most of nitroaromatic
compounds, with the genotoxicity being attributed to the
reduced metabolites that are bioactivated by these bacterial
enzymes (absent in human cells).30 Thus it is accepted that the
comet assay or the micronucleus assay are more pertinent
methods to evaluate the genotoxic potential of nitroaromatic
compounds. For example, fexinidazole is positive in the Ames
test but negative in the micronucleus assay.31 A comet assay
was then performed on the HepG2 cell line with hit compound
12, using methylmethanesulfonate (MMS) as a positive
control (see the Supporting Information). Compound 12
was not genotoxic after 2 or 72 h of incubation or at 1 or 10
μM, concentrations chosen to be lower than its CC50 on
HepG2 cell line (CC50 = 18 μM).
Regarding tolerance in the mouse, a once daily oral dose of
compound 12, at 25 or 50 mg/kg, was administrated to eight
mice (four mice in each group). These two doses were well
tolerated with just a little apathy during 1 h for all mice
receiving the dose of 50 mg/kg. The administration of a
repeated dose of 25 mg/kg once daily for 5 days was well
tolerated without any adverse effect noted. The no-observed-
adverse-effect level (NOAEL)31 in mice was then set at 25 mg/
kg/day. After euthanasia, no lesions were found on the
different organs (kidney, liver, brain, heart, and lung).
Finally, the in vivo pharmacokinetic parameters were
determined in the mouse, after oral administration at 25 mg/
kg in a mixture of 5% Tween 80 and 95% of 0.5%
carboxymethylcellulose in water, by using the QuEChERS
method.32 Monolix Lixoft software was used to analyze the
data by a noncompartmental model to fit pharmacokinetics
parameters.33 As presented in the Supporting Information
(Figure S17), hit-compound 12 showed good pharmacokinetic
properties: 12 is highly and rapidly absorbed after oral
administration and shows good exposure. Its plasmatic half
life (2.9 h) is higher than the one of the drug fexinidazole (0.8
h).31
Conclusions. Via an antitrypanosomal pharmacomodula-
tion study of the 8-nitroquinolin-2(1H)-one scaffold, by
introducing an EWG at positions 3 and 6 of the quinolinone
ring, a novel potent antitrypanosomal hit-compound (12) was
identified, displaying high activities toward T. b. brucei (EC50 =
12 nM) and T. cruzi (EC50 = 0.5 μM) in comparison with
eflornithine (EC50 = 13 μM), suramin (EC50 = 30 nM),
benznidazole (EC50 = 0.5 μM), and fexinidazole (EC50 = 0.4
and 3.0 μM). Compound 12 displays good in vitro
pharmacokinetic parameters (good microsomal stability and
BBB permeability), is rapidly absorbed after oral adminis-
tration, and is well tolerated in the mouse at 25 mg/kg.
Nitroaromatic hit compound 12 is selectively bioactivated by
type 1 NTR in both Leishmania and Trypanosoma. An
electrochemistry study showed the strong influence of the
introduction of an EWG in the benzenic part of the
pharmacophore toward the redox potentials and the
corresponding antitrypanosomal activities. Finally, the lack of
genotoxicity of compound 12 in the comet assay is an
additional favorable element so as to consider further
development. Compound 12 meets all criteria for an
antitrypanosomal hit, as defined by Katsuno and coworkers.34
In vivo studies on the mice model of trypanosomiasis are now
planned to investigate the potential of this compound to
become an antitrypanosomal lead.
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Table 3. Evaluation of the Bioactivation of Compounds 7,
12, and 13 by Leishmanial and Trypanosomal NTRs
Leishmania donovani promastigotes EC50 (μM)
compound wild type NTR1 overexpressing NTR2 overexpressing
Hit 1 5.9 ± 0.2 0.47 ± 0.02 4.6 ± 0.12
7 4.1 ± 0.2 1.2 ± 0.05 4.9 ± 0.3
12 4.7 ± 0.09 0.3 ± 0.01 2.9 ± 0.08
13 2.0 ± 0.2 1.3 ± 0.1 2.1 ± 0.1
Trypanosoma brucei brucei trypomastigotes EC50 (μM)
compound wild type NTR overexpressing
Hit 1 17.7 ± 1.0 3.9 ± 0.1
Hit 2 5.4 ± 0.12 4.2 ± 0.2
7 6.7 ± 0.4 0.9 ± 0.03
12 0.3 ± 0.06 0.02 ± 0.008
13 4.0 ± 0.2 0.1 ± 0.009
Nifurtimox 1.9 ± 0.05 0.6 ± 0.05
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